@Interesting article - US drug initiation on Shift.ms

Forum

Charity Number: 1117194 (England and Wales)

Registered Company: 06000961

Registered address:
Shift.ms, Platform, New Station Street, LS1 4JB, United Kingdom

London office:
Shift.ms, Somerset House, Strand, West Goods Entrance, London WC2R 1LA, United Kingdom

@DominicS

Last reply

Interesting article - US drug initiation

Nice that they have numbers in (n=x) and some interesting observations. As a Brit I think that another of the reasons that some people appear to delay treatment may be financial, even if they say otherwise. https://www.prnewswire.com/news-releases/spherix-global-insights-recent-multiple-sclerosis-chart-audit-shows-that-the-current-first-line-opportunity-for-high-efficacy-disease-modifying-therapies-including-genentechs-ocrevus-and-biogens-tysabri-may-be-limited-by-a-sm-300793638.html

@Stumbler

@dominics , as this is American data, there's the hoops imposed by the health insurance companies as well. Who really knows what the key drivers are behind DMT choice?

13 Feb 2019 11:06

@DominicS

@stumbler. I agree, which is why I mention it. The article doesn't and I think they have missed something. Harder for a consultancy to investigate and measure and may even be perceived as over-political for their audience. Thank god for the NHS eh?

13 Feb 2019 11:12